BioNexus Gene Lab Corp. reports developments in precision diagnostics, genomic screening, and its Malaysia-based industrial chemicals subsidiary. The company operates through Chemrex Corporation Sdn. Bhd., which distributes chemical raw materials for industrial applications, and MRNA Scientific Sdn. Bhd., which develops blood-based genomic screening services for disease risk assessment and health management.
Recent company updates center on VitaGuard™, a minimal residual disease liquid biopsy platform for oncology monitoring, including Southeast Asia commercialization rights, regional deployment planning, laboratory and clinical collaborations, and its strategic investment in Fidelion Diagnostics. Other recurring announcements cover subsidiary governance at Chemrex, reporting controls, material agreements, and equity financing arrangements supporting the company’s diagnostics and biotechnology initiatives.
BioNexus (Nasdaq: BGLC) introduced its BGLC 1Lab laboratory workflow product through a controlled GeneMatrix-focused pilot at subsidiary MRNA Scientific. BioNexus has built GeneMatrix Enterprise and completed internal workflow testing. The pilot in Penang, Malaysia, will evaluate traceability and staff review before wider deployment.
Clinical release remains subject to validation and security, privacy, regulatory and management reviews. BioNexus plans to integrate Ruanyun Edai Technology’s CogniAI document-processing platform after the anticipated closing of their Malaysian license agreement. That agreement remains subject to technology delivery, written acceptance, due diligence and required approvals; commercial deployment can begin only after closing.
BioNexus Gene Lab (Nasdaq: BGLC) launched a redesigned corporate website that brings together business information and expanded investor resources. The site covers MRNA Scientific’s RNA screening business, Chemrex’s industrial chemical and composite-materials business, and BioNexus’ healthcare investments and technology relationships.
Technology pages describe blood-based genomic screening and the VitaGuard molecular residual disease platform. The expanded investor-relations section provides reports, SEC filings, governance materials and shareholder information, while the newsroom gathers announcements, events and presentation resources.
BioNexus Gene Lab (Nasdaq: BGLC) signed an agreement with Ruanyun Edai Technology for an exclusive Malaysian healthcare licence to CogniAI. BioNexus plans to develop applications for public healthcare digitalization, but has no government contract. The licence would run for ten years from closing, with two five-year renewal options; exclusivity is subject to milestone, cure and termination provisions.
At closing, BioNexus would issue 410,000 common shares for stated US$3.5 million licence consideration and another 150,000 shares for 500,000 RYET ordinary shares. No cash payment is required. RYET would receive 10% of defined technology receipts collected. Closing remains subject to technology delivery, written acceptance, satisfactory due diligence and required approvals. Delivery is due December 4, 2026; either non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended.
Ruanyun Edai Technology (RYET) signed a definitive agreement to license Cogni AI exclusively to BioNexus Gene Lab for Malaysian healthcare. At closing, RYET would receive 560,000 BGLC shares and entitlement to a 10% royalty on qualifying technology receipts. The license would run ten years, with BGLC options extending it to 20 years. RYET would issue 500,000 ordinary shares in the reciprocal exchange.
The contractual license consideration is US$3.5 million, payable in 410,000 BGLC shares whose quoted value was US$520,700 on October 2, 2026; it is not GAAP revenue. No minimum royalty or revenue is guaranteed. Closing remains subject to technology acceptance, due diligence and required approvals. Technology delivery is due within 60 days of signing unless extended in writing. A non-defaulting party may terminate if closing has not occurred by March 31, 2027, unless extended. Neither company has a contract under the cited government programs.
BioNexus (Nasdaq: BGLC) reported progress toward commercializing the VitaGuard™ molecular residual disease (MRD) liquid‑biopsy platform in Southeast Asia after a working visit to Tongshu Gene facilities and Chinese hospitals where VitaGuard is in paid commercial use. The visit, led by Fidelion’s Chief Commercial Officer, focused on technical planning, workflows, documentation, reagents, and commercial routes.
Under a November 2025 assignment, Fidelion holds VitaGuard IP rights outside China and has licensed BioNexus exclusive commercialization rights in ten Southeast Asian markets, covering use, development, manufacture, marketing and sale. BioNexus also owns about 15% of Fidelion, giving it direct regional and indirect global exposure.
BioNexus has previously indicated an expected cost per VitaGuard test of under US$300, subject to local factors, and sees potential for repeat MRD monitoring across a regional population of over 680 million. The company is preparing documentation transfer, local verification/validation, and regulatory steps in Malaysia and Singapore, targeting initial deployments in select regional medical hubs during 2026, subject to approvals.
BioNexus Gene Lab (Nasdaq:BGLC) highlighted its role at the 2026 China–Malaysia Economic Cooperation Outlook Forum, advocating deeper Malaysia–China biotechnology cooperation beyond trade. CEO Sam Tan outlined a Malaysia-based ASEAN execution hub for precision diagnostics, liquid biopsy, MRD monitoring, AI-integrated healthcare, and public-market-supported regional commercialization platforms.
BioNexus Gene Lab Corp (NASDAQ: BGLC) announced March 11, 2026 the appointment of Dr. Muthu Meyyappan as Chief Commercial Officer of Fidelion Diagnostics to lead global commercialization of the VitaGuard™ MRD platform. Fidelion is the international commercialization vehicle for VitaGuard™, and BGLC is a strategic investor holding exclusive Southeast Asia commercialization rights via licensing. Dr. Meyyappan brings 15+ years of global oncology diagnostics and liquid biopsy commercial leadership to advance laboratory, clinical, and pharma partnerships for international adoption.
BioNexus Gene Lab Corp (Nasdaq: BGLC) completed a governance restructuring at wholly owned subsidiary Chemrex, streamlining the Chemrex board to two directors and appointing Matthew L. Barsing as chairman on February 23, 2026. Financial supervision and reporting at Chemrex were consolidated to align with parent governance.
The BioNexus Board previously authorized a staged capital allocation framework in July 2025 to evaluate potential Chemrex expansion initiatives; no definitive commitments or timelines have been made.
BioNexus (Nasdaq: BGLC) announced the 2026 Deployment Phase for its VitaGuard™ MRD platform, aiming to scale affordable longitudinal cancer monitoring across Southeast Asia.
The company targets replacement of legacy tests costing over $3,000, cites an ASEAN population of 680 million, and references projected regional cancer incidence of 2.4 million by 2030. BGLC says it completed global patent work, established Fidelion Diagnostics Pte. Ltd. for IP commercialization outside Greater China, and plans initial regional deployments and healthcare partnerships during 2026.
BioNexus Gene Lab Corp (NASDAQ: BGLC) completed a strategic transaction with Fidelion Diagnostics and Tongshu Biotechnology on Dec 3, 2025. BGLC acquired a 15% equity stake in Fidelion via a non‑cash share swap and secured exclusive, perpetual commercial rights to the VitaGuard™ Tumor‑Naïve MRD liquid biopsy platform across all ASEAN markets.
The deal pairs a commercial asset (ASEAN manufacturing, marketing, distribution) with an investment asset (equity exposure to Fidelion). The license fee is payable over 24 monthly installments. Fidelion will hold approximately 16.6% of BGLC, aligning mutual interests and enabling joint regional studies, regulatory engagement, and market rollout.